A new open-access study published in BMC Immunology points to a small regulatory molecule as a potential player in that process. Researchers report that the microRNA miR-892b is under-expressed in patients with sepsis-induced myocardial dysfunction, while the gene CTNNB1 is overexpressed, and that the two molecules show a negative correlation with each other.
Using a dual-luciferase reporter assay, the team validated that miR-892b targets CTNNB1, directly downregulating its expression. In their patient samples, the inverse relationship between the two molecules was accompanied by evidence that miR-892b displayed good diagnostic efficacy for sepsis-induced myocardial dysfunction, suggesting it could serve as a biomarker candidate.
To probe function, the researchers established a laboratory model in which H9c2 cells, a commonly used cardiac muscle cell line, were damaged with lipopolysaccharide (LPS), a bacterial wall component that drives inflammatory injury. In this model, LPS downregulated miR-892b in a dose- and time-dependent manner, meaning that higher exposure and longer exposure both pushed the microRNA’s levels further down. That pattern positioned miR-892b as a plausible mediator of the injury response rather than a passive bystander.
When the team increased miR-892b in the damaged cells, several markers of injury improved. Cell viability rose, apoptosis declined, and the release of inflammatory mediators, measured by ELISA, was inhibited. These protective effects, however, depended on CTNNB1: overexpressing CTNNB1 reversed the cardioprotective effects of miR-892b. Together, the experiments sketch a pathway in which loss of miR-892b during inflammatory stress lifts restraint on CTNNB1, contributing to cell damage, and restoring the microRNA re-establishes that restraint.
The authors conclude that miR-892b alleviates LPS-induced cardiomyocyte damage by inhibiting CTNNB1 expression and may serve as a potential diagnostic predictor and therapeutic target for sepsis-induced myocardial dysfunction. The findings come from clinical correlation measurements by RT-qPCR and from cell-culture experiments, so they establish associations and mechanism in a model system rather than clinical benefit in patients. Even so, the study adds a defined molecular axis to the search for tools that could identify, and eventually counter, the cardiac injury that makes sepsis so dangerous.
Subject of Research: The role of miR-892b and its target CTNNB1 in sepsis-induced myocardial dysfunction.
Article Title: miR-892b targeting CTNNB1 regulates sepsis-induced myocardial dysfunction
Article References: Mei, L., Yu, X., Zhang, Y., & Cao, J. (2026). miR-892b targeting CTNNB1 regulates sepsis-induced myocardial dysfunction. BMC Immunology. https://doi.org/10.1186/s12865-026-00908-7
Image Credits: AI Generated
DOI: 10.1186/s12865-026-00908-7
Keywords: miR-892b, CTNNB1, sepsis-induced myocardial dysfunction, microRNA, H9c2 cells, lipopolysaccharide, apoptosis, inflammatory cytokines, RT-qPCR, dual-luciferase reporter assay, BMC Immunology, targeting
News Source: Ophelia Keating. (October 29, 2026). MicroRNA miR-892b curbs sepsis-related heart damage by targeting CTNNB1. Scienmag.



